Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome (NCT04792463)
๐ฉบ Plain-English Summary (8th-Grade Level)
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screening and earlier intervention which would improve the treatment outcome not only for retaining vision but also for overall survival. Similarly in patients with germline BAP1 mutation CM develops in premalignant atypical melanocytic lesions and careful follow up of these patients will improve the outcome of their disease. In addition this study could have impact on the management of patients with personal and/or family history of several other cancers reported in patients with germline BAP1 mutation such as mesothelioma, renal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, meningioma and basal cell carcinoma.
Who can join: Review the eligibility criteria below.
Location: The Ohio State University Wexner Medical Center โ Columbus, Ohio
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- The Ohio State University Wexner Medical Center โ Columbus, Ohio
๐ Contact the Study Coordinator
Phone: (614) 292-1396
Email: Mohamed.Abdel-Rahman@osumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Uveal Melanoma
- (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma โ Scottsdale, Arizona
- A Prospective Natural History Study in Uveal Melanoma โ Boston, Massachusetts
- Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma โ Tampa, Florida
- Psychoeducation for Uveal Melanoma โ Los Angeles, California
- Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma โ Tampa, Florida
Explore by condition: All Uveal Melanoma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.